Join Abvance Therapeutics for a key opinion leader (KOL) virtual event to discuss the promise of an insulin and glucagon pharmacological combination, already evaluated in subjects with Type 1 diabetes, and designed to improve overall glycemic control while reducing hypoglycemia for people who require insulin treatment.

The event, moderated by Katie Ellias, Managing Director of the T1D Fund, will feature a panel discussion with distinguished KOLs and an overview of the Abvance product pipeline. KOL and Abvance corporate participants will include:

• David Maggs, MD, FRCP, co-founder and CEO of Abvance Therapeutics
• Carol Wysham, MD, Clinical Professor of Medicine at the University of Washington School of Medicine and Clinical Endocrinologist at MulticareRockwood Clinic
• Steven Smith, MD, Senior Vice President and Chief Scientific Officer of AdventHealth
• Sean Sullivan, PhD, Program Officer for the Helmsley Charitable Trust Type 1 Diabetes Program

A live question and answer session will follow the panel discussion.